Drug Watch

Accropeutics reveals promising Phase 2 trial results for AC-201, a selective TYK2/JAK1 inhibitor, showing significant efficacy in treating plaque psoriasis.

Albert Chiou, MD, MBA, discusses early clinical data on soquelitinib for atopic dermatitis, highlighting its targeted ITK inhibition, dose-dependent efficacy, favorable safety profile, and more.

Scott Batty, MD, and Chris VanDeusen, PhD, provided insights on AX-158's phase 2a results, presented at the SID Annual Meeting.

The promising safety and efficacy results were presented at the Society for Investigative Dermatology 2025 Annual Meeting.

Selective ITK inhibition with oral soquelitinib led to early and durable clinical responses, cytokine reduction, and increased T regulatory cells.

The FDA approved pz-cel, a groundbreaking gene therapy for recessive dystrophic epidermolysis bullosa, transforming treatment options for patients.

Dupilumab becomes the first targeted therapy approved for chronic spontaneous urticaria in more than a decade.

Having multiple therapeutic options would allow clinicians to tailor treatment and offer hope to patients who don't respond initially.

While approved for vitiligo and atopic dermatitis, ruxolitinib cream may help treat other inflammatory skin diseases.

Exclusive Q1 Report: A comprehensive look at the latest FDA approvals and pipeline developments in dermatology from the first quarter of 2025.

The novel treatments will be for patients with orphan conditions like Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, and palmoplantar keratoderma.

A pilot study revealed that mitochondrial complex I-blocking drugs, like metformin and berberine, improved TSW symptoms in most participants.

Christopher Bunick, MD, PhD, discussed how to interpret recent benzene research as clinicians await regulatory guidance for benzoyl peroxide.

Christopher Bunick, MD, PhD, explains what comes next for clinicians and patients live at AAD 2025.

The recall includes L'Oréal's Effaclar Duo product. Stay tuned for more updates throughout the day.

Medicus’ previous phase 1 study confirmed D-MNA’s safety, with some participants achieving complete BCC clearance.

Shawn Kwatra, MD, FAAD, reviews his late-breaking data presentation at AAD on the first original studies of a topical cream for prurigo nodularis.

The company showcased advancements in tirbanibulin and its early-stage antibody LAD191.

Published in JID, the study analyzes data from the FDA’s FAERS database to examine cases of neoplasms—including skin and breast cancers—potentially associated with benzoyl peroxide use.

The findings of the MVOR-1 and MVOR-2 studies are published in JAMA Dermatology, supporting the rosacea drug’s recent FDA approval.

After just 2 weeks of twice-daily use, a pediatric patient saw visually improved skin with no adverse events.

DELTA China follows the success of European and Canadian trials, reinforcing delgocitinib’s potential as a global treatment for CHE.

A PDUFA target action date has been set for October 13, 2025.

Snail slime contains bioactive compounds that promote skin healing, hydration, and regeneration.